Individual Participant Data (IPD) Meta-analyses of Diagnostic and Prognostic Modeling Studies: Guidance on Their Use by Debray, T.P. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/152362
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
GUIDELINES ANDGUIDANCE
Individual Participant Data (IPD) Meta-
analyses of Diagnostic and Prognostic
Modeling Studies: Guidance on Their Use
Thomas P. A. Debray1,2*, Richard D. Riley3, Maroeska M. Rovers4, Johannes
B. Reitsma1,2, Karel G. M. Moons1,2, Cochrane IPD Meta-analysis Methods group¶
1 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The
Netherlands, 2 The Dutch Cochrane Centre, Julius Center for Health Sciences and Primary Care, University
Medical Center Utrecht, Utrecht, The Netherlands, 3 Research Institute for Primary Care and Health
Sciences, Keele University, Staffordshire, The United Kingdom, 4 Radboud Institute for Health Sciences,
Radboudumc Nijmegen, The Netherlands
¶ Membership of the Cochrane IPDMeta-analysis Methods group is listed in the Acknowledgments.
* T.Debray@umcutrecht.nl
Introduction
A fundamental part of medical research is the development and validation of diagnostic and
prognostic prediction models [1,2]. These prediction models aim to predict the absolute proba-
bility that a certain disease or condition is currently present (diagnostic models) or that an out-
come will occur within a specific follow-up period (prognostic models) for an individual
subject.
Prediction models typically rely on multiple predictors, which can include demographic
characteristics, medical history and physical examination items, or more complex measure-
ments from, for example, medical imaging, electrophysiology, pathology, and biomarkers. Also
Summary Points
• Individual participant data meta-analyses (IPD-MAs) provide unique opportunities
not only for therapeutic studies but also for diagnostic and prognostic prediction
modeling studies.
• IPD-MAs of prediction modeling studies allow for more robust development of predic-
tion models, as well as for directly validating them and testing their generalizability
across different (sub)populations and settings.
• Methods for IPD-MA of prediction modeling studies fundamentally differ from other
types of IPD-MA research, because of the focus on the estimation of absolute risks and
the importance of covariates.
• When heterogeneity is present in an IPD-MA of prediction models, special care is
needed to enable tailoring of the prediction model to (sub)populations or settings at
hand, to enhance their generalizability and usefulness.
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for diagnostic models, estimates of probabilities are rarely based on a single test, and doctors
naturally integrate several patient characteristics and symptoms [3]. A broad range of predic-
tion modeling techniques exist, like regression approaches, neural network models, decision
tree models, genetic programming models, and support vector machine learning models,
although prediction models developed by a multivariable regression approach are by far
prevailing.
It is widely recommended that a developed prediction model should not be used in practice
before being externally validated—at least once—in other individuals than those used for
model development [4–7]. Unfortunately, most prediction models are poorly or not at all vali-
dated, rendering interpretation of their generalizability difficult. In addition, many systematic
reviews showed that for the same outcome or same target population, numerous competing
models exist [8–10]. Generally speaking, researchers often ignore existing prediction models
and develop yet another prediction model from their own data [2]. This practice sustains a
cycle of underpowered prediction model development studies and poor knowledge about the
generalizability and applicability of developed prediction models. Evidence synthesis and
meta-analysis of individual participant data (IPD) from multiple studies seems to be a unique
opportunity to address these problems, as it allows researchers to develop and directly validate
models on large datasets and across a wide range of populations and settings, to directly test a
model’s generalizability (Fig 1) [11–13].
There is currently little guidance on how to conduct an IPD meta-analysis (IPD-MA) for
developing and/or validating diagnostic or prognostic prediction models [15]. To date, most
IPD-MA articles focus on estimating relative quantities, like a risk ratio, hazard ratio, or odds
ratio for a specific treatment or a specific etiologic factor. In contrast, prediction modeling
research is focused on developing and validating multivariable models aimed at calculating an
absolute risk estimate of the combined variables, rather than estimating the relative effect of a
specific treatment or etiologic factor. Furthermore, prediction modeling studies focus entirely
on the role and joint contribution of multiple covariates, whereas intervention studies in prin-
ciple rely on randomization to reduce the role of covariates (Table 1). Hence, IPD-MAs of ran-
domized intervention and etiological studies, which are beyond the scope of this paper and are
Fig 1. Trends in publications of IPD-MA studies focusing on the development and/or validation of diagnostic or prognostic predictionmodels.
Number of publications per year focusing on diagnostic, prognostic, or either type of IPD-MA. Results were identified by applying the search strategy of Riley
et al. [14] in PubMed on March 24, 2015. A sensitive filter was applied to identify those publications explicitly mentioning the study aim (diagnosis, prognosis,
or prediction) in the title.
doi:10.1371/journal.pmed.1001886.g001
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instead addressed in the accompanying paper [16], differ from IPD-MAs of multivariable pre-
diction models, which are the focus of this paper.
We provide an overview of the advantages and limitations of IPD-MAs aiming to develop a
novel prediction model or to validate one or more existing models across multiple datasets.
This overview is based on published guidelines and existing recommendations for the conduct
of prediction modeling studies and of IPD-MA research. We illustrate this overview with
examples of recently published IPD-MAs of prediction models across various medical
domains. Our aim is to help researchers, readers, reviewers, and editors to identify and under-
stand the key issues involved with such IPD-MA projects.
Types of IPD-MA of Prediction Modeling Studies
Several types of IPD-MA can be distinguished. When a single (previously published) predic-
tion model is available, typical research aims include the following:
• To validate and summarize the model’s performance across various study populations, set-
tings, and domains. For example, Geersing and colleagues used an IPD-MA to examine the
predictive accuracy of the Wells rule for diagnosing deep vein thrombosis (DVT) across dif-
ferent subgroups of suspected patients [17].
Table 1. The main differences between IPD-MA of treatment intervention studies and of multivariable prediction modeling studies.
Intervention Research Diagnostic/Prognostic Modeling Research
General Issues
Primary aim Estimation of therapeutic effect of a speciﬁc treatment Estimation of the probability of the presence (diagnosis) or future
occurrence (prognosis) based on combinations of two or more
predictors
Secondary aims Treatment effect in study subgroups Evaluate accuracy of model predictions across subgroups,
settings, or countries
Estimates of interest (Adjusted) treatment-outcome associations (Distribution of) individual outcome probabilities/risks;
discrimination and calibration of estimated model probabilities
Association measures Relative risk estimates: risk ratio, hazard ratio, risk
difference, and odds ratio
Absolute probability or risk estimates of the outcome at interest
Study design Randomized studies Observational research (randomized study data sometimes also
used)
Data retrieval
Study registration Clinical Trials registry (http://clinicaltrials.gov/) No such registry
Developing search
query
Extensive Cochrane Collaboration guidance, including
search ﬁlters
Recent but less evolved guidance (by Cochrane Collaboration)
Assessing risk of bias Risk of Bias tool (Cochrane Collaboration) CHARMS tool (Cochrane Collaboration)
Data analysis
Statistical model Models yielding valid estimates of relative treatment effects Models yielding absolute outcome probabilities
Relevance of covariates Covariates may be included to adjust for baseline
imbalance and to investigate potential effect modiﬁers
Covariates (other predictors) are explicitly included to increase
the model’s predictive accuracy
Dealing with between-
study heterogeneity
Random-effects modeling of treatment effect, inclusion of
treatment-covariate interactions, meta-regression, and
subgroup analysis
Stratiﬁcation of baseline risk across studies, focus on
homogeneous and weakly heterogeneous predictors, and
inclusion of interaction terms and nonlinear predictor effects
Validation of research
ﬁndings
Comparison of model ﬁt, sensitivity analyses, and
recursive cumulative meta-analysis
Evaluation of model discrimination and calibration; internal,
internal-external, and external validation
Measures of precision Standard error, p-value, conﬁdence intervals of (relative)
treatment effect, and prediction intervals
Conﬁdence and prediction intervals of model discrimination and
calibration
Abbreviations: CHARMS, Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies
doi:10.1371/journal.pmed.1001886.t001
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• To tailor (update) the model to specific populations or settings. For instance, Majed and col-
leagues evaluated whether the calibration of the Framingham risk equation for coronary
heart disease and stroke improved by applying local adjustments [18].
• To examine the added value of a specific predictor or (bio)marker to the model across differ-
ent study populations, settings, and domains. For example, an IPD-MA was performed to
summarize the added value of common carotid intima-media thickness (CIMT) in 10-year
risk prediction of first-time myocardial infarctions or strokes in the general population,
above that of the Framingham Risk Score [19].
When various competing prediction models are available that were developed for the same
target population or the same outcome across various study populations, typical research aims
of an IPD-MA include the following:
• To compare the models’ performance across various study populations, settings, and
domains. For instance, an IPD-MA was used to validate and compare all noninvasive risk
scores for the prediction of developing type 2 diabetes in individuals of the general popula-
tion [20].
• To combine the most promising models and adjust them to specific study populations, set-
tings, and domains. This approach is illustrated by Debray and colleagues, who validated and
updated all existing diagnostic models for predicting the presence of DVT across different
settings and proceeded to combine them into a single meta-model [21].
Finally, when no prediction models are available, an IPD-MA can be used to develop and
directly validate a new prediction model using the IPD from all relevant studies. An example is
the development of the prognostic PHASES score for prediction of risk of rupture of intracra-
nial aneurysms in patients with aneurysms but without any treatment [22].
Advantages and Challenges of an IPD-MA in Prediction Research
Box 1 summarizes the general advantages and challenges of IPD-MA in prediction studies. An
IPD-MA of prediction models has a major advantage not only in developing more robust pre-
diction models because of the increased sample size but also in directly validating the models
and hence revealing their clinical usefulness. This combination of development, validation, and
testing for usefulness can be applied across different patient subgroups, different target popula-
tions, and even different care settings, if such datasets are included in the IPD-MA. Whereas a
single prediction modelling study is usually confined to quantifying the average predictive per-
formance of the prediction model across the entire study population, an IPD-MA allows for
quantifying subgroup- or setting-specific performances, and the prediction model can even be
tailored to optimize its performance in these specific (sub)groups or settings. For example,
Geersing and colleagues examined the diagnostic accuracy of the Wells prediction rule for
diagnosing DVT across different subgroups of suspected patients and evaluated whether the
rule had to be tailored to enhance its accuracy in these subgroups [17]. Table 2 highlights
unique advantages of IPD access for different research aims.
Ahmed and colleagues recently provided over 20 recommendations to improve the develop-
ment and validation of prediction models using IPD from multiple studies [15]. We here elabo-
rate on five key aspects of IPD-MA of prediction models: prespecifying the IPD-MA,
identifying the relevant studies for the IPD-MA, assessment of risk of bias of individual stud-
ies/datasets, implementation of appropriate statistical methods, and reporting of results.
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Prespecifying the IPD-MA
It is important for IPD-MA projects that one a priori defines the rationale, methods, conduct,
and analyses of the IPD-MA [23]. When IPD-MA projects are based on a systematic review,
the protocol should also indicate which type of publications are deemed relevant. Researchers
may, for instance, seek all publications that have already developed or validated a prediction
model for a specific target population, specific setting, or for specific outcome(s) [24–26].
Alternatively, researchers may seek all publications that used a dataset that fit the IPD-MA
Box 1. Advantages and Challenges of IPD-MA of Multivariable
Prediction Modeling Studies, Based on Ahmed and colleagues [15]
Advantages
• Increases the total sample size. This reduces the risk of incidental findings, increases
the precision of study results, and enables the development of more robust prediction
models.
• Increases the available case-mix variability. This enhances the potential generalizability
of prediction models across subgroups, settings, and countries.
• Ability to standardize analysis methods across IPD sets. For example, one can stan-
dardize the type of statistical model used (such as Cox, logistic or other model), the
predictor and outcome definitions, and the methods to account for differences in cen-
soring and in lengths of follow-up.
• Ability to investigate more complex associations, such as nonlinearity of predictor
effects, predictor interactions, and time-varying predictor effects.
• Ability to explore heterogeneity in the predictive performance of the models—for
example, in whom (in which subgroups, countries, or settings) or under which circum-
stances does a prediction model not perform adequately.
• Ability to evaluate generalizability and thus usability of prediction models across differ-
ent situations.
Challenges
• Unavailability of IPD in some studies and assessing the impact of their absence on pre-
dictive performance of a developed or validated prediction model.
• Methodological quality assessment of primary prediction modeling studies is yet less
well developed.
• Dealing with different definitions of predictors and outcomes; with different data
sources (such as prospective and retrospective cohort studies, case-control studies,
case-cohort studies, or randomized trials); and with different (or outdated) treatment
strategies, especially when older and newer primary studies are combined.
• Dealing with missing data, including partially missing predictors and outcome data, as
well as completely missing predictors in some studies.
• Dealing with heterogeneity in predictor effects and outcome occurrence across the
included primary studies.
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objective. Study protocols are certainly relevant for IPD-MAs that are prospectively planned
and should ideally be accessible for inspection by external parties [23,27,28]. By setting com-
mon quality standards and standardizing predictor definitions, measurement methods, and
outcome recoding, the consistency across included datasets increases, thereby reducing the risk
of bias. Study protocols may also help to convince other researchers to participate in the
IPD-MA and to share their IPD. Examples of relevant databases for protocols of systematic
reviews are the Cochrane Library (www.thecochranelibrary.com) and the International Pro-
spective Register of Systematic Reviews (www.crd.york.ac.uk/prospero/).
Identifying the Relevant Studies for the IPD-MA
Various competing strategies can be initiated for collecting the relevant studies in an IPD-MA
[15]. Similar to meta-analyses of randomized trials of treatments [16,29,30], these studies
should ideally be identified through a systematic review. However, it is also possible to prospec-
tively set up a collaborative group of selected researchers active on the same topic who agree to
share their IPD. Examples of such collaborations are the European Prospective Investigation
into Cancer and Nutrition (N> 520,000 from ten European countries) [31] and the Emerging
Risk Factors Collaboration (N> 2.2 million participants in 125 prospective studies) [32]. Fur-
thermore, if there are known relevant studies that did not provide their IPD, it may help to
extract their summary information. Examples of such information are measures of model per-
formance including c-statistic and calibration slopes with their 95% confidence intervals and
estimated predictor effects. Recently, methods have been developed to combine such summary
estimates with the results from the IPD-MA [21,33,34].
Assessing Risk of Bias of Included Studies
Similar to any type of systematic review, the quality of an IPD-MA of prediction models strongly
depends upon the methodological quality of included studies. When these studies have flaws in
the design, conduct, or analysis, the IPD-MAmay yield biased estimates of predictive perfor-
mance. Researchers should therefore evaluate the methodological quality in each of the included
prediction model studies. The CHARMS checklist is a very recent guideline and checklist for
data extraction and critical appraisal of primary prediction model studies in systematic reviews
[35]. This checklist may also be used for critically appraising the primary prediction modeling
studies to be included in the IPD-MA. Progress on a formal risk-of-bias tool for prediction
Table 2. Overview of types (aims) of IPD-MAs of predictionmodeling studies.
Starting
Point
Use IPD Datasets to Apply Meta-analysis to What Aggregate Data
Can Be Used?
IPD Access Allows to
Existing
prediction
model(s)
Validate these
models.
Pool estimates of model discrimination
and calibration.
Published estimates of
the predictive
performance
Investigate sources of heterogeneity in
model performance; identify which
models perform best in what (sub)
population, setting, or country.
Existing
prediction
model(s)
Tailor (update) or
combine these
models.
Adjust for between-study heterogeneity in
outcome occurrence and/or predictor
effects.
Published prediction
models and published
predictor effects
Combine and tailor the model(s) to
speciﬁc (sub)populations, settings, or
countries.
Existing
prediction
model(s)
Investigate added
value of new
predictor(s) to
existing model.
Pool estimates of added value (such as
adjusted predictor effect or improvement
in model calibration, discrimination, and/
or reclassiﬁcation).
Published estimates of
added value of speciﬁc
predictor to a speciﬁc
model
Investigate sources of heterogeneity in
added value; identify relevant
subgroups that yield different added
value.
No existing
prediction
model(s)
Develop new model. Adjust for between-study heterogeneity in
outcome occurrence or predictor effects.
Published predictor
effects
Tailor the meta-model to speciﬁc (sub)
populations, settings, or countries.
doi:10.1371/journal.pmed.1001886.t002
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modeling studies, developed by various authors around the globe, including co-conveners of the
Cochrane Prognosis Methods Group, is underway (www.systematic-reviews.com/probast/).
Statistical Methods
The statistical analysis approach of an IPD-MA of prediction models has to deal with several
key issues. We here elaborate on missing data and between-study heterogeneity. Another key
issue is the combination of IPD and aggregate data from the literature (Table 2). Combining
IPD and aggregate data for the development and validation of multivariable prediction models
is, however, not straightforward and therefore beyond the scope of this paper. Statistical meth-
ods for this purpose have previously been described [21,33,34,36].
Missing Data
Missing data basically appear when subject characteristics have not fully been recorded within
the primary studies or were measured inconsistently across studies (for example, a predictor
that was measured on a continuous versus categorical scale), so-called partial missing data.
Missing data may also arise when some of the included studies did not measure a certain pre-
dictor at all, the so-called systematically missing predictors [37–39]. In any case, it is increas-
ingly acknowledged that missing data should be addressed using multiple imputation
techniques; this should also be done in IPD-MAs. These techniques generate (multiple) com-
pleted versions of each original dataset. For partial missing data, imputation can be applied
separately for each study of the IPD-MA to allow for heterogeneity in associations between
observed and missing predictors. However, when there is a mixture of partial and systemati-
cally missing data, more advanced imputation techniques are needed to simultaneously impute
the IPD from each study in the IPD-MA [37,38].
Between-Study Heterogeneity
Between-study heterogeneity arises when the studies of an IPD-MA yield substantially differ-
ent estimates of model performance (for example, when validating an existing prediction
model), of a predictor’s added predictive value (for example, when examining the added value
of a certain predictor to an existing prediction model), or of certain predictor effects (for exam-
ple, when developing a novel prediction model). Researchers should therefore investigate the
presence of heterogeneity across the available studies and check whether its extent can be
reduced or explained. As a first step, researchers may compare the characteristics of included
studies and populations. Depending on the research aim of the IPD-MA, different methods
can then be applied to account for the presence of between-study heterogeneity.
When externally validating one or more prediction models in an IPD-MA, it is recom-
mended to investigate the influence of specific study characteristics such as case-mix differ-
ences on the predictive performance of the models [40,41]. This could reveal under which
circumstances the model remains valid and how the model may be improved upon for different
subgroups or settings. The presence of between-study heterogeneity in model performance can
be investigated using traditional (random effects) techniques that are sometimes used in the
analysis of multinational or multicenter randomized trials. For instance, Kengne and colleagues
validated all existing models for predicting the development of type 2 diabetes in the general
population, separately in different countries, and then pooled the resulting performance esti-
mates using a traditional random effects model [20]. When such random effects analysis con-
veys substantial heterogeneity in the performance of a prediction model in a certain country,
(sub)population, or setting, an IPD-MA allows one to tailor or update the prediction model to
enhance its performance in that specific country, subpopulation, or setting. An example is the
PLOSMedicine | DOI:10.1371/journal.pmed.1001886 October 13, 2015 7 / 12
validation and updating of the sex-specific Framingham risk equation for coronary heart dis-
ease and stroke [18]. An IPD-MA was used to adjust this model for the baseline survival and
mean predictor values of each included country and to re-estimate country-specific predictor
effects. The study concluded that the updated model, despite yielding poor discrimination,
achieved better calibration in a European population of middle-aged men.
When investigating the added value of a specific (new) predictor to existing predictors, it is
recommended to verify whether this added predictive value substantially varies across the
included studies of an IPD-MA and, if so, to evaluate under which circumstances and in which
types of individuals or settings it can be used as an addition to existing predictors or models.
For example, Den Ruijter and colleagues tested heterogeneity in the added value of CIMT
above that of the Framingham Risk Score by exploring the presence of interaction between
cohort membership and CIMT [19]. Because no evidence for heterogeneity was found and
because the improvement in 10-year risk prediction of first-time myocardial infarction or
stroke was small, they concluded that the addition of CIMT on top of Framingham Risk Score
is unlikely to be of clinical importance.
When developing a novel prediction model from an IPD-MA, researchers may quantify the
degree of variation in outcome frequency and in predictor effects across the IPD-MA studies
using traditional meta-analysis methods [11]. This information could then be used to decide
which and how predictors will be included during the statistical analyses. It has been demon-
strated that using average predictor effects (for instance, as obtained from random effects mod-
els) is detrimental when their association substantially varies across studies [11]. For this
reason, efforts should be made to facilitate tailoring of the model to new study populations.
This can, for instance, be achieved by applying stratification, by omitting predictors with het-
erogeneous effects, or by considering nonlinear terms and interaction effects. In contrast to
prediction models developed from a single dataset, an IPD-MA has the unique feature of
directly applying internal-external cross validation of a developed model [11,13,42]. This
method iteratively discards one study of the IPD-MA for external validation purposes and uses
the remaining studies for the model development. This directly allows one to investigate
whether a developed model predicts differently across certain populations, settings, or even
subgroups and whether the model would differ in fit for purpose when applied in practice.
Also, it is an ideal method to deal with between-study heterogeneity to determine the extent of
the generalizability and thus applicability of the developed model. Finally, when the calibration
and discrimination performance measures from an internal-external cross validation are
pooled using a multivariate meta-analysis approach [40], it is even possible to evaluate whether
a prediction model’s average performance varies across different subgroups, populations, or
settings. This in turn helps to identify under what circumstances in clinical practice the model
can reliably be used and when and whether a developed model first requires tailoring to specific
clinical situations to enhance its usefulness for the situation at hand.
Reporting IPD-MA of Prediction Modeling Studies
Similar to meta-analysis of randomized trials of interventions [43], IPD-MA should be
reported fully and transparently as well, to allow readers to assess the strengths and weaknesses
of the investigation. Although specific guidelines are currently lacking, important issues to
report should clearly include details on study identification, study inclusion and exclusion cri-
teria, predictor and outcome definitions, the amount of missing subject-level and missing
study-level data, the presence of between-study heterogeneity, and how this is dealt with [15].
Furthermore, to address potential concerns over selective nonpublication, authors should
explain whether analyses could be completed as planned or why they had to be revised. Further
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—but less specific—guidance can be found in the recent Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA)-IPD reporting statement [44] and in the very
recent Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or
Diagnosis (TRIPOD) reporting guideline for studies on developing, validating, or updating a
prediction model [3,45].
Conclusions
Systematic review and meta-analysis of IPD is widely recognized as a gold standard approach
in intervention research and is equally pivotal in prediction modeling research. Having IPD
from multiple studies is particularly useful for improving the performance of novel prediction
models across different study populations, settings, and domains and to attain a better under-
standing of the generalizability of prediction models. It is, however, important to acknowledge
that IPD-MAs are no panacea against poorly conceived and conducted primary studies. Well-
designed prospective studies remain paramount and could, for instance, benefit by involving
multiple centers or countries and applying IPD-MA methodology. Prospective studies are also
needed for evaluating the impact of prediction models on decision making and patient out-
comes. The guidance provided in this article may help researchers to decide upon appropriate
strategies when conducting an IPD-MA in prediction modeling research and assist readers,
reviewers, and practitioners when evaluating the quality of resulting evidence.
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